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Summary
Background Joint symptoms (eg, arthralgia and arthritis) are a well-known side-eﬀ ect of aromatase inhibitors. Low 
oestrogen concentrations and postmenopausal status are associated with the development of these symptoms. 
Chemotherapy can also induce joint symptoms, but tamoxifen seems to have little eﬀ ect on their incidence. The aim 
of this study was to assess the relative importance of diﬀ erent risk factors for treatment-emergent joint symptoms in 
patients assigned to anastrozole or tamoxifen as adjuvant treatment for postmenopausal breast cancer.
Methods The Arimidex Tamoxifen Alone or in Combination (ATAC) trial randomly assigned 9366 postmenopausal 
women to anastrozole (1 mg/day), to tamoxifen (20 mg/day), or to a combination of both. Our analyses were based on 
data from case reports of 5433 women who were randomly assigned to anastrozole or tamoxifen, who started with 
their allocated treatment, and who did not have joint symptoms at entry (anastrozole group: n=2698; tamoxifen group: 
n=2735). The analysis was restricted to the occurrence of joint symptoms at any time during active treatment or 
within 14 days of its discontinuation. Joint symptoms were deﬁ ned as any report of arthralgia, arthrosis, arthritis, 
or joint disorder on a case-report form. Joint disorders were deﬁ ned as reports of cervical spondylosis, osteoarthritis, 
and disc herniation. The date of occurrence was recorded, along with a severity score (ie, mild, moderate, or severe). 
Our analyses were done by use of logistic regression. The ATAC trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN18233230.
Findings 777 of 1914 women (40·6%) who used hormone replacement therapy (HRT) before trial entry developed joint 
symptoms compared with 1001 of 3519 women (28·4%) without previous HRT use (odds ratio [OR] 1·72 [95% CI 
1·53–1·93]). Women with hormone-receptor-negative breast cancer developed signiﬁ cantly fewer joint symptoms 
compared with those with hormone-receptor-positive tumours (124 of 461 [26·9%] vs 1556 of 4548 [34·2%]; OR 0·71 
[0·57–0·88]). Women for whom chemotherapy was part of their initial treatment developed signiﬁ cantly more joint 
symptoms than those who did not receive it (461 of 1219 women [37·8%] vs 1317 of 4214 women [31·3%]; OR 1·34 
[1·17–1·53]). Obese women (body-mass index [BMI] >30 kg/m²) reported more joint symptoms than women with a BMI 
of 25–30 kg/m² or those with a BMI <25 kg/m² (504 of 1354 women [37·2%] vs 502 of 1926 women [31·3%; OR 1·01 
(0·88–1·16)] vs 592 of 1908 women [31·0%; OR 1·32 (1·14–1·53)]) and women on anastrozole reported more joint 
symptoms compared with those on tamoxifen (949 of 2698 women [35·2%] vs 829 of 2735 women [30·3%]; OR 1·25 
[1·11–1·40]). All signiﬁ cant risk factors from the univariate analysis were included in a multivariate analysis and remained 
signiﬁ cant with little change.
Interpretation In this trial, the major risk factors for developing joint symptoms were previous HRT, hormone-
receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole. Discussion of identiﬁ ed risk 
factors is appropriate when counselling women before initiation of adjuvant hormonal treatment.
Funding This study was funded by Cancer Research UK and AstraZeneca (Macclesﬁ eld, UK).
Introduction
Oestrogen deﬁ ciency has been associated with joint 
symptoms (eg, arthralgia and arthritis) in several diﬀ erent 
settings. In the general population, postmenopausal 
status and low oestrogen concentrations are associated 
with the development of joint pain and joint symptoms.1,2 
These symptoms are most prominent around the ages of 
50 to 59 years,1,2 are more common in postmenopausal 
women than in premenopausal and perimenopausal 
women of the same age,3 and often improve during use 
of hormone replacement therapy (HRT).4,5
Further evidence linking joint symptoms with de-
creased oestrogen concentrations comes from adjuvant 
trials of aromatase inhibitors in patients with early breast 
cancer, where increased joint symptoms (eg, arthralgia 
and arthritis) have been noted for all three third-
generation aromatase inhibitors.6–8 Women treated with 
chemotherapy for breast cancer have also shown joint 
symptoms and other joint or muscle-related problems.9,10 
However, tamoxifen does not seem to have an eﬀ ect on 
joint symptoms. In the ﬁ rst International Breast Cancer 
Intervention Study,11 joint symptoms were similarly 
distributed between treatment groups in postmenopausal 
women (159 of 3579 women in the tamoxifen group vs 
147 of 3575 women in the placebo group; p=0·5). Similar 
ﬁ ndings were shown in the Royal Marsden trial.12 In this 
retrospective, exploratory analysis, we investigate the 
relative importance of a range of risk factors for joint 
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symptoms in the Arimidex Tamoxifen Alone or in 
Combination (ATAC) trial,13 and assess whether these 
risk factors act diﬀ erently in the presence of anastrozole 
treatment. 
Methods
The ATAC trial13 was a double-blind randomised clinical 
trial in which postmenopausal women with early breast 
cancer were randomly assigned to oral daily anastrozole 
(1 mg) alone, tamoxifen (20 mg) alone, or a combination 
of both in a double-blind fashion, so that each woman 
took two tablets, at least one of which was active. 
Patients from the combination group were discontinued 
after 33 months of follow-up and are not included in 
this analysis. Women were followed-up at 3 months, 
6 months, and then at 6 monthly intervals for the 5 years 
of active treatment. Details of trial design, methods, 
primary objectives, and outcome have been published 
elsewhere.13 Written informed consent was obtained 
from all participants before trial entry. Regulatory and 
ethics authorities for all participating centres in 
21 countries approved the protocol before enrolment of 
participants. The trial was done in accordance with the 
Declaration of Helsinki (1996 revision) and under the 
principles of good clinical practice. 
Only women who started with their randomly assigned 
treatment and who did not report joint symptoms at entry 
were included in this analysis (anastrozole group: n=2698; 
tamoxifen group: n=2735). Women with joint symptoms 
at entry reported fewer symptoms during treatment. By 
excluding these women, we focused on newly reported 
joint symptoms, which are more likely to be related to 
endocrine treatment. Our analysis was based on the 
100-month median follow-up data set, at which point all 
patients had completed their study medication.14 Because 
most symptoms occurred relatively early, and the eﬀ ects 
of treatment and other variables were not constant with 
time, the analysis was restricted to the occurrence of joint 
symptoms at any time during active treatment or within 
14 days of its discontinuation. Joint symptoms were 
deﬁ ned as any report of arthralgia, arthrosis, arthritis, or 
joint disorder (Coding Symbols for a Thesaurus of 
Adverse Reaction terms)15 on a case-report form. Joint 
disorders were deﬁ ned as reports of cervical spondylosis, 
osteoarthritis, and disc herniation. The date of occurrence 
was recorded, along with a severity score (ie, mild, 
moderate, or severe). For the ATAC trial, all side-eﬀ ect 
data were the result of elicited responses recorded on 
case-report forms and a speciﬁ c symptom check list was 
not used. All reports were reviewed by the trial medical 
oﬃ  cer (FS), who was blinded to treatment allocation, to 
resolve any uncertain reports.  
Statistical analysis
Analyses of potential risk factors were based on 
comparisons of proportions by univariate and multivariate 
logistic regression. Interactions between treatment and 
subgroups were based on likelihood ratio tests for an 
added interaction term. Hazard plots were smoothed by 
use of an Epanechnikov kernel with the optimum 
bandwidth chosen by cross validation.16 All p values are 
two-sided, with level of signiﬁ cance set at 0·05, and all 
conﬁ dence intervals are at the 95% level. All calculations 
were done by use of STATA (version 9.2).
The ATAC trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN18233230.
Safety population Study population
Anastrozole* (N=3092) Tamoxifen (N=3094) OR (95% CI) Anastrozole* (N=2698) Tamoxifen (N=2735) OR (95% CI)
Overall, n (%) 1128 (36·5) 957 (30·9) 1·28 (1·15–1·43) 949 (35·2%) 829 (30·3%) 1·25 (1·11–1·40)
Mild, n (%) 586 (19·0) 517 (16·7) 1·16 (1·02–1.33) 518 (19·2%) 472 (17·3%) 1·14 (0·99–1·31)
Moderate, n (%) 447 (14·5) 353 (11·4) 1·31 (1·13–1·53) 366 (13·6%) 296 (10·8%) 1·29 (1·09–1·53)
Severe, n (%) 94 (3·0) 87 (2·8) 1·08 (0·79–1·47) 64 (2·4%) 61 (2·2%) 1·06 (0·73–1·54)
OR=odds ratio. *One patient in the anastrozole group reported joint symptoms but severity was not provided. 
Table 1: Patients with joint symptoms by severity and treatment ﬁ rst received for all women (safety population) and for those without joint symptoms 
















Anastrozole 2698 2239 1950 1710 1534 1354 
Tamoxifen 2735 2372 2085 1859 1656 1464 
Anastrozole
Tamoxifen
Figure 1: Patients (%) developing joint symptoms at or before a speciﬁ ed follow-up time during active 
treatment according to treatment ﬁ rst received in women without joint symptoms at entry (study 
population)
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Role of the funding source
This study was funded by Cancer Research UK and 
AstraZeneca (Macclesﬁ eld, UK). All authors were 
responsible for data interpretation and writing the report, 
and the decision to submit for publication was taken 
jointly with the Steering Committee. IS and JC had full 
access to the data. The commercial sponsor was 
represented by two of the 28 members of the Steering 
Committee.  
Results
A total of 2085 of 6186 women in the safety population 
reported joint symptoms while on active treatment. 
Signiﬁ cantly more joint symptoms were noted in the 
anastrozole group compared with the tamoxifen group 
(1128 of 3092 (36·5%) vs 957 of 3094 (30·9%); odds ratio 
[OR] 1·28 [95% CI 1·15–1·43), p<0·0001). 394 women in 
the anastrozole group and 359 women in the tamoxifen 
group (OR 0·90 [0·77–1·05]) reported a history of joint 
symptoms at entry into the trial. These women have been 
excluded from further analyses. Table 1 shows exclusion 
of these women had little eﬀ ect on the diﬀ erences in 
joint symptoms between the two treatment groups. After 
exclusion, a total of 2698 women in the anastrozole group 
and 2735 women in the tamoxifen group remained for 
further analyses (study population). Figure 1 shows the 
higher prevalence of joint symptoms reported by women 
without a history of joint symptoms at study entry in the 
anastrozole group compared with the tamoxifen group. 
Most of the additional joint symptoms reported in the 
anastrozole group occurred during the ﬁ rst 2 years of 
treatment (ﬁ gure 2). In both treatment groups, most 
joint symptoms were of mild or moderate severity, and 
the intensity of symptoms was similarly distributed in 
both treatment groups (table 1). 1067 of 1778 patients 
(60%) who reported joint symptoms received treatment, 
with 960 of these patients (90%) using a non-steroidal 
anti-inﬂ ammatory drug alone or in combination with a 
mild analgesic.
Potential risk factors for developing joint symptoms 
are shown for each treatment group in table 2. After 
exclusion of women with baseline joint symptoms, 949 of 
2698 women (35·2%) reported joint symptoms in the 
anastrozole group compared with 829 of 2735 women 
(30·3%) in the tamoxifen group (OR 1·25 [95% CI 
1·11–1·40; p<0·0001]; table 3). For women who previously 
used HRT, 777 of 1914 (40·6%) developed joint symptoms 
compared with 1001 of 3519 women (28·4%) without 
previous HRT use (OR 1·72 [1·53–1·93]; p<0·0001). Joint 
symptoms were increased by a similar amount for women 
who stopped HRT less than 6 months before trial entry 
compared with those who stopped HRT more than 
6 months before entry (502 of 1201 women (41·8%) vs 
142 of 335 women (42·4%); OR 1·08 [0·84–1·40]; p=0·54). 
133 patients with joint symptoms and 245 patients without 
joint symptoms had missing data for date of last use. 
Women with hormone-receptor-negative breast cancer 
developed signiﬁ cantly fewer joint symptoms than those 
with hormone-receptor-positive tumours (124 of 461 
(26·9%) vs 1556 of 4548 (34·2%); OR 0·71 [0·57–0·88]; 
p=0·002; table 3). Previous chemo therapy was also a 
strong risk factor for developing joint symptoms (461 of 





Previous HRT 941 (34·9) 973 (35·6)
Previous chemotherapy 627 (23·2) 592 (21·6)
Previous radiotherapy 1796 (66·6) 1780 (65·1)
History of smoking 1092 (40·5) 1118 (40·9)
BMI (kg/m2)
<25 963 (35·7) 963 (35·2)
25–30 957 (35·5) 969 (35·4)
>30 654 (24·2) 700 (25·6)
Missing 124 (4·6) 121 (4·4)
Hormone-receptor status 
Positive (ER or PgR positive) 2264 (83·9) 2284 (83·5)
Negative 220 (8·2) 241 (8·8)
Unknown 214 (7·9) 210 (7·7)
Region
UK 905 (33·5) 910 (33·3)
ROW 991 (36·7) 1016 (37·1)
North America* 802 (29·7) 809 (29·6)
Age (years)
≤60 993 (36·8) 1016 (37·1)
61–70 1019 (37·8) 998 (36·5)
>70 686 (25·4) 721 (26·4)
HRT=hormone replacement therapy. BMI=body-mass index. ER=oestrogen 
receptor. PgR=progesterone receptor. ROW=rest of world. *North America=USA 
and Canada.























Figure 2: Smoothed annual hazard rates (%) of newly reported joint symptoms during active treatment 
according to treatment ﬁ rst received in women without joint symptoms at entry (study population)
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chemotherapy vs 1317 of 4214 women (31·3%) with history 
of no chemotherapy; OR 1·34 [1·17–1·53]; p<0·0001). 
Women with a BMI over 30 kg/m² and those who smoked 
reported more joint symptoms than their counterparts 
(table 3). Age and radiotherapy showed no detectable 
eﬀ ect on the development of joint symptoms. 
When all signiﬁ cant variables in the univariate models 
were entered into a multivariate model, the odds ratios 
were similar to the univariate ﬁ ndings, except for 
smoking status, which became non-signiﬁ cant (table 3). 
Similar ﬁ ndings for the univariate and multivariate 
analyses of risk factors were obtained if the population 
was restricted to hormone-receptor-positive women (data 
not shown). Additionally, there were no signiﬁ cant 
interactions of any factors with treatment, except for a 
weak interaction between treatment and previous HRT 
use (pinteraction=0·05; table 4).   
Women from the USA and Canada (grouped as North 
America) reported signiﬁ cantly more joint symptoms 
than those from the UK or the reference group of the rest 
of the world (738 of 1611 (45·8%; OR 2·44 [2·12–2·80]; 
p<0·0001) vs 523 of 1815 (28·8%; OR 1·17 [1·01–1·35]; 
p=0·03) vs 517 of 2007 (25·8%); table 3). This diﬀ erence 
was unchanged in the multivariate model. To explore 
further baseline characteristics, interactions of region 
with other key variables were added to the model. Overall, 
Women with joint symptoms, n (%) Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Treatment
Tamoxifen (n=2735) 829 (30·3) 1 1
Anastrozole (n=2698) 949 (35·2) 1·25 (1·11–1·40) <0·0001 1·26 (1·12–1·42) <0·0001
Previous HRT 
No (n=3519) 1001 (28·4) 1 1
Yes (n=1914)* 777 (40·6) 1·72 (1·53–1·93) <0·0001 1·53 (1·35–1·74) <0·0001
   Stopped ≤6 months† (n=1201) 502 (41·8) 1
   Stopped >6 months† (n=335) 142 (42·4) 1·08 (0·84–1·40) 0·54‡ ·· ··
Chemotherapy  
No (n=4214) 1317 (31·3) 1 1
Yes (n=1219) 461 (37·8) 1·34 (1·17–1·53) <0·0001 1·24 (1·07–1·43) 0·004
Hormone-receptor status 
Positive (ER or PgR positive; n=4548) 1556 (34·2) 1 1
Negative (n=461) 124 (26·9) 0·71 (0·57–0·88) 0·002 0·78 (0·62–0·98) 0·03
Unknown (n=424) 98 (23·1) 0·58 (0·46–0·73) <0·0001 0·76 (0·59–0·97) 0·028
Region
ROW (n=2007) 517 (25·8) 1 1
UK (n=1815) 523 (28·8) 1·17 (1·01–1·35) 0·03 1·20 (1·02–1·40) 0·025
North America§ (n=1611) 738 (45·8) 2·44 (2·12–2·80) <0·0001 2·09 (1·79–2·43) <0·0001
BMI (kg/m2)¶
<25 (n=1908) 592 (31·0) 1 1
25–30 (n=1926) 602 (31·3) 1·01 (0·88–1·16) 0·88 1·08 (0·94–1·24) 0·28
>30 (n=1354) 504 (37·2) 1·32 (1·14–1·53) <0·0001 1·33 (1·14–1·55) <0·0001
Ever smoker
No (n=3223) 1030 (32·0) 1 1
Yes (n=2210) 747 (33·8) 1·12 (1·00–1·26) 0·05 0·99 (0·88–1·12) 0·9
Age (years)
≤60 (n=2009) 661 (32·9) 1 ·· ··
61–70 (n=2017) 638 (31·6) 0·94 (0·83–1·08) 0·39 ·· ··
>70 (n=1407) 479 (34·0) 1·05 (0·91–1·22) 0·49 ·· ··
Radiotherapy
No (n=1857) 644 (34·7) 1 ·· ··
Yes (n=3576) 1134 (31·7) 1·05 (0·93–1·18) 0·40 ·· ··
Reference group is represented by an odds ratio (OR) of 1. Multivariate analysis includes only signiﬁ cant factors from the univariate model. HRT=hormone-replacement 
therapy. ER=oestrogen recepetor. PgR=progesterone receptor. ROW=rest of world. BMI=body-mass index. *Stop-date data missing for 133 patients with joint symptoms and 
245 patients without joint symptoms. †Before trial entry. ‡Comparison with those who used HRT and excludes 133 patients with missing data for stop date. §North 
America=USA and Canada. ¶Data missing for 245 patients.
Table 3: Risk factors at baseline for developing joint symptoms in women without joint symptoms at trial entry (study population)
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no signiﬁ cant interactions of key variables in the 
univariate model were seen with region in the multivariate 
model (data not shown). 
Discussion
In this trial, the major risk factors for developing joint 
symptoms in women not reporting them at entry 
were previous HRT use, hormone-receptor positivity, 
previous chemotherapy, obesity, and treatment with 
anastrozole versus tamoxifen, leading to signiﬁ cant 
absolute increases of 12·1%, 7·3%, 6·5%, 6·2%, and 
4·9%, respectively. All these factors are potentially linked 
with greater decreases in oestrogen concentrations near 
to the time when endocrine treatment is started. Women 
with pre-existing joint symptoms were excluded from this 
analysis to focus on new treatment-emergent symptoms.
The eﬀ ect of previous HRT was especially striking, 
which could be because most women previously using 
HRT, for whom we had data, came oﬀ  it within 6 months 
before entry into the study (1201 of 1536 women [78·2%]), 
although the eﬀ ect was similar in women who had 
stopped their HRT treatment earlier. Furthermore, the 
eﬀ ects of HRT seemed to be additive, resulting in an 
18·1% increase in joint symptoms in women who 
previously used HRT and were on anastrozole compared 
with those on tamoxifen with no previous HRT use. 
Recent users of HRT (ie, those who stopped use less than 
6 months ago) are likely to have a greater decrease in 
oestrogen concen trations with endocrine treatment than 
those who stopped use more than 6 months ago, and 
most,17,18 but not all studies,19 have shown that they are 
more likely than never users to have oestrogen-receptor-
positive tumours. In our study, women with hormone-
receptor-positive tumours reported more joint symptoms 
than those with hormone-receptor-negative tumours, 
but, paradoxically, the few women with tumours of 
unknown hormone-receptor status had the lowest 
number of joint symptoms. Several studies have shown 
that women with high oestrogen concentrations are more 
likely to develop oestrogen-receptor-positive tumours 
than those with low oestrogen concentrations.20, 21
Obese women tend to have higher oestrogen concen-
trations than non-obese women as a result of aroma-
tisation from the adipose tissue,22 so the decrease in 
oestrogen concentration is likely to be greater in this 
group as well. Obesity itself is also a risk factor for joint 
symptoms independent of endocrine treatment.23 How-
ever, Crew and colleagues24 reported that women with a 
BMI between 25 and 30 kg/m² developed fewer joint 
symptoms than those with a lower BMI. Our data do not 
conﬁ rm this ﬁ nding, with signiﬁ cantly more joint 
symptoms being noted with increasing BMI. 
Chemotherapy is well known to induce arthralgia or 
myalgia and has been reported in several trials in-
dependently of endocrine treatment.10,25–27 Chemo -
therapy is known to damage ovarian function in 
premeno pausal women, and the eﬀ ects seen here could 
be a result of the ablation of any residual ovarian 
production of oestrogen in these postmenopausal 
women. Again, the ﬁ ndings were additive in anastrozole 
users so that the use of previous chemotherapy and 
anastrozole together resulted in a 12·4% increase in 
joint symptoms when compared with women on 
tamoxifen without previous chemo therapy.
Reports have suggested that side-eﬀ ects, such as joint 
symptoms, are under-reported in clinical trials compared 
with patient-recorded side-eﬀ ects.28,29 The ATAC trial 
was an international study, involving 21 countries. Joint 
symptoms were collected in free-text format on the case-
report forms. Because of the nature of the collection, in 
which uniform deﬁ nition of symptoms was not provided, 
subcategories of joint symptoms were not thought to be 
reliable and were, therefore, not reported during the 
ATAC trial. Additionally, the duration of symptoms and 
date of resolution of symptoms could not be assessed in 
detail, because data were collected at 3 months, 
6 months, and at 6-monthly intervals thereafter, so dates 
within these intervals were not recorded. Because the 
study was blinded, there would have been no bias in 
relative rates, but the overall reporting rates for speciﬁ c 
symptoms could have been aﬀ ected. However, this 
approach did seem to be sensitive, because known 
minor side-eﬀ ects, and some previously unknown ones, 
were clearly detectable.30 The symptoms were assessed 
by clinicians and mapped to the relevant COSTART 
Anastrozole (N=2698) Tamoxifen (N=2735) pinteraction
All 949 (35·2) 829 (30·3)
Previous HRT
No 525/1757 (29·9) 476/1762 (27·0) ··
Yes 424/941 (45·1) 353/973 (36·3) 0·05
Chemotherapy
No 687/2071 (33·2) 630/2143 (29·4) ··
Yes 262/627 (41·8) 199/592 (33·6) 0·20
Hormone-receptor status 
Positive (ER or PgR positive) 840/2264 (37·1) 716/2284 (31·3) ··
Negative 59/220 (26·8) 65/241 (27·0) 0·23
Unknown 50/214 (23·3) 48/210 (22·9) 0·31
Region
ROW 284/991 (28·7) 233/1016 (22·9) ··
UK 269/905 (29·7) 254/910 (27·9) 0·15
North America* 396/802 (49·4) 342/809 (42·3) 0·94
BMI (kg/m2)†
<25 324/963 (33·6) 268/945 (28·4) ··
25–30 335/957 (35·0) 267/969 (27·6) 0·48
>30 246/654 (37·6) 258/700 (36·9) 0·21
HRT=hormone replacement therapy. ER=oestrogen receptor. PgR=progesterone receptor. ROW=rest of world. 
BMI=body-mass index *North America=USA and Canada. †Data missing for 245 patients.
Table 4: Number (%) of women reporting joint symptoms at any time during treatment according to 
treatment ﬁ rst received and selected risk factors in women without joint symptoms at entry (study 
population)
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terms.15 This ascertainment of joint symptoms needs to 
be taken into account when interpreting these ﬁ ndings. 
Although various joint symptoms were reported during 
the study, only 1% of them led to treatment withdrawal. 
By contrast, a higher drop-out rate caused by joint 
symptoms was reported in two smaller uncontrolled 
studies,31,32 but it is diﬃ  cult to attribute all these events 
to an aromatase inhibitor, because joint symptoms are 
common in postmenopausal women (eg, 31% of women 
receiving tamoxifen in the ATAC trial reported joint 
symptoms).
The increased incidence of joint symptoms in the 
North American population is most probably consistent 
with diﬀ erent practices for recording symptoms. 
Although more patients had previous HRT use, 
previous chemotherapy, and a higher BMI in North 
America, compared with the UK and the rest of the 
world, the eﬀ ects of region were only slightly diminished 
when they were adjusted for in the multivariate model. 
No signiﬁ cant interactions between region and risk 
factors were identiﬁ ed, suggesting that the diﬀ erences 
noted between regions were most probably due to 
diﬀ erent thresholds for reporting these symptoms in 
North America, especially because adverse events 
overall were more often reported in North American 
participants.
In conclusion, several factors other than treatment with 
anastrozole were associated with the development of 
joint symptoms in this trial. The eﬀ ects are additive and 
thus need to be taken into account when counselling 
women about the use of aromatase inhibitors. Joint 
symptoms were generally of mild to moderate intensity 
and for most women they do not override the clear 
beneﬁ ts of anastrozole over tamoxifen in terms of 
decreased recurrence and fewer other major side-eﬀ ects, 
including venous thromboembolic events and 
gynaecological complications (eg, endometrial cancer).14 
However, for women with serious side-eﬀ ects on 
anastrozole, tamoxifen remains a viable option. 
Awareness of risk factors for joint symptoms will help 
both clinicians and patients to anticipate and manage 
these symptoms and ensure optimum adherence to 
endocrine treatment.
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